Background: Chronic kidney disease (CKD) affects approximately 15% of adults in the USA.
As CKD progresses, urinary phosphate excretion decreases and results in phosphate …

Introduction Among the clinical and metabolic complications of progressive chronic kidney
disease (CKD), CKD-mineral bone disorder (CKD-MBD) significantly contributes to morbidity …

Background Treating hyperphosphatemia is a tenet of dialysis care. This trial assessed the
safety and efficacy of tenapanor for the management of hyperphosphatemia. Methods In this …

Aims The kidneys play a major role in maintaining Pi homeostasis. Patients in later stages of
CKD develop hyperphosphatemia. One novel treatment option is tenapanor, an intestinal …

Constipation is a frequent symptom in patients with chronic kidney disease (CKD). This
review outlines the mechanisms and management of constipation in patients with CKD from …

Intestinal phosphorus absorption: recent findings in transla... : Current Opinion in Nephrology
and Hypertension Intestinal phosphorus absorption: recent findings in translational and clinical …

Purpose: This narrative review explores the currently published studies that have evaluated
tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) …

The critical importance of phosphate regulation in chronic kidney disease (CKD) has been
well understood for decades. But new findings, frequently applicable to routine medical care …

Phosphate homeostasis is dependent on the interaction and coordination of four main organ
systems: thyroid/parathyroids, gastrointestinal tract, bone and kidneys, and three key …

Background: Most patients with end-stage kidney disease and hyperphosphatemia have
difficulty controlling serum phosphate concentrations (sP) despite maintenance dialysis …